Studies of how long people stay on a GLP-1 reflect different care settings. The study of weight outcomes at a UK online clinic uses recorded follow-up weights, while this study measured persistence through active prescriptions. The French study followed 191 adults with severe obesity in a structured early-access program at one French center [1]. The program supplied semaglutide at no cost to patients.
Who was still on treatment at 48 weeks
At week 48, 97 of 122 people who completed the optional baseline assessment remained on treatment (79.5%). The figure was 23 of 32 partial users (71.9%) and 22 of 37 nonusers (59.5%) [1].
Each step up in engagement was associated with higher adjusted odds of continuing treatment. The estimated odds ratio was 1.62 (95% CI 1.05 to 2.50). Participants chose how much of the assessment to complete. The study defined persistence as an active prescription at the 48-week visit.
What a questionnaire can tell us
Research on why people stop taking GLP-1 drugs describes barriers in other settings. Here, time, language, internet access or other differences could affect both completion and persistence.
The association cannot show what would happen if a clinic assigned the questionnaire. Persistence percentages from this program may differ from those in other settings.